Quadrant Capital Group LLC Cti Biopharma Corp Transaction History

Quadrant Capital Group LLC

  • $1.42 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023
SELL
$4.45 - $6.17 $836 - $1,159
-188 Reduced 24.07%
593 $3,000
Q3 2022

Nov 10, 2022
BUY
$5.36 - $7.43 $1,007 - $1,396
188 Added 31.7%
781 $5,000
Q2 2022

Aug 09, 2022
BUY
$3.55 - $6.27 $2,105 - $3,718
593 New
593 $4,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email